Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aims: Tacrolimus, metabolized by CYP3A4 and CYP3A5 enzymes, is susceptible to drug-drug interactions (DDI). Steroids induce CYP3A genes to increase tacrolimus clearance, but the effect is variable. We hypothesized that the extent of the steroid-tacrolimus DDI differs by CYP3A4/5 genotypes.
Methods: Kidney transplant recipients (n = 2462) were classified by the number of loss of function alleles (LOF) (CYP3A5*3, *6 and *7 and CYP3A4*22) and steroid use at each tacrolimus trough in the first 6 months post-transplant. A population pharmacokinetic analysis was performed by nonlinear mixed-effect modelling (NONMEM) and stepwise covariate modelling to define significant covariates affecting tacrolimus clearance. A stochastic simulation was performed and translated into a Shiny application with the mrgsolve and Shiny packages in R.
Results: Steroids were associated with modestly higher (3%-11.8%) tacrolimus clearance. Patients with 0-LOF alleles receiving steroids showed the greatest increase (11.8%) in clearance compared to no steroids, whereas those with 2-LOFs had a negligible increase (2.6%) in the presence of steroids. Steroid use increased tacrolimus clearance by 5% and 10.3% in patients with 1-LOF and 3/4-LOFs, respectively.
Conclusions: Steroids increase the clearance of tacrolimus but vary slightly by CYP3A genotype. This is important in individuals of African ancestry who are more likely to carry no LOF alleles, may more commonly receive steroid treatment, and will need higher tacrolimus doses.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bcp.16172 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Population pharmacokinetics and bioavailability of tacrolimus oral suspension in children with haematopoietic stem cell transplant.
Br J Clin Pharmacol
August 2025
Unit of Innovative Treatments, Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina.
Aims: Model-informed precision dosing of tacrolimus is crucial to minimize toxicity and prevent graft-vs.-host disease in children undergoing haematopoietic stem cell transplantation (HSCT). Therefore, we developed a population pharmacokinetic model of tacrolimus oral suspension in paediatric HSCT patients that could be used for routine care.
View Article and Find Full Text PDFA Tacrolimus Population Pharmacokinetic Model for Adult Allogeneic Hematopoietic Cell Transplant Recipients Provides Clinical Opportunities for Precision Dosing.
Clin Pharmacokinet
August 2025
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA.
Background: Tacrolimus is a cornerstone of acute graft-versus-host disease (aGVHD) prophylaxis in allogeneic hematopoietic cell transplant (allo-HCT) recipients. However, a narrow therapeutic index and high interindividual variability in pharmacokinetics (PK) make starting dose selection a major challenge in clinical practice.
Methods: Data from two PK studies conducted at the University of North Carolina Medical Center (UNCMC) were used to develop an oral tacrolimus population pharmacokinetic (popPK) model specific to adult allo-HCT recipients.
Clinical significance and gene prediction of a novel classification system based on tacrolimus concentration-to-dose ratio in the early post-liver transplant period.
Front Pharmacol
July 2025
Department of General Surgery, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Background And Aims: Classification system of tacrolimus elimination and its clinical significance has not been well described in liver transplantation. This study aimed to present a novel tacrolimus clearance clinical-FIS (Fast-Intermediate-Slow) classification and its gene prediction system.
Methods: Patients from 3 transplant centers were enrolled in this study.
Machine learning-assisted tacrolimus dose optimization in childhood- onset systemic lupus erythematosus through population pharmacokinetic modeling.
Comput Biol Med
September 2025
National-Local Joint Engineering Laboratory of Druggability and New Drug Evaluation, National Engineering Research Center for New Drug and Druggability (cultivation), Guangdong Province Key Laboratory of New Drug Design and Evaluation, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guang
Objective: This study aimed to improve treatment effectiveness in childhood-onset systemic lupus erythematosus (cSLE) by developing machine learning algorithms integrated with pharmacokinetic parameters to predict individualized tacrolimus dosing for optimized therapy.
Methods: Data from 480 trough tacrolimus concentrations in 86 cSLE patients over five years were analyzed. A nonlinear mixed-effects model was constructed to characterize the pharmacokinetics of tacrolimus.
Polymer-free tacrolimus microsphere implants for long-acting prevention of corneal neovascularization in rats by subconjunctival injection.
J Control Release
September 2025
School of Pharmaceutical Sciences (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen 518107, China. Electronic address:
Corneal neovascularization (CNV) severely compromises vision and remains difficult to manage with current pharmacotherapies, which are often limited by rapid drug clearance, poor tissue penetration, and adverse effects. Although polymer-based drug carriers can provide sustained drug release, they frequently suffer from low drug-loading capacity, suboptimal release kinetics, or induce inflammatory responses. Tacrolimus (FK506), a potent immunosuppressant with anti-inflammatory activity, is similarly limited by poor water solubility and rapid ocular clearance when administered as eye drops.
View Article and Find Full Text PDF